Trial Profile
A Phase 4, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Comparative Study and a Phase 4, Multicenter, Open-label, Long-term Study to Evaluate the Safety and Efficacy of SYR-472 When Orally Administered at a Dose of 100 mg Once Weekly as an add-on to Insulin Therapy in Patients With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Despite Treatment With Insulin Preparations in Addition to Diet and/or Exercise Therapy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Trelagliptin (Primary) ; Insulin
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Takeda
- 25 Jan 2017 Status changed from active, no longer recruiting to completed.
- 28 Jan 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 02 Dec 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.